A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND: Novel glucagon-like peptide-1 receptor agonists (GLP1RAs) for obesity treatment have generated considerable dialogue on digital media platforms. However, nonevidence-based information from online sources may perpetuate misconceptions abou…
BACKGROUND: Implementation of semaglutide weight loss therapy has been challenging due to drug supply and cost, underscoring a need to identify those who derive the greatest absolute benefit. OBJECTIVES: Allocation of semaglutide was modeled accordin…
AIM: This real-world, retrospective cohort study aimed to assess the efficacy, safety and tolerability of oral semaglutide-the first GLP-1 receptor agonist available in oral form-in patients aged 65 years and older with type 2 diabetes mellitus (T2DM…
OBJECTIVE: To identify patients who may or may not benefit from use of new drugs for weight loss and to aid in minimizing loss of lean mass through proactive nutrition and exercise interventions. QUALITY OF EVIDENCE: Choices and interventions are eva…
BACKGROUND: People with schizophrenia have a 16-20-year reduction in life expectancy, primarily due to cardiometabolic disease. Clozapine, the most efficacious antipsychotic for treatment-resistant schizophrenia, is associated with weight gain and me…
INTRODUCTION: Traditionally, obstructive sleep apnea (OSA) management has focused on continuous positive airway pressure therapy, oral appliances, and in some cases, surgical interventions. However, these treatments do not directly address the underl…
"Ozempic face" and facial aging have been observed as side effects in many patients after glucagon like peptide 1 receptor agonists (GLP-1RA) therapy for type 2 diabetes mellitus (T2DM) and obesity. However, those medications can reduce systemic infl…
Semaglutide, a GLP-1 receptor agonist, has emerged as a promising agent in cardiovascular disease management, particularly for patients with obesity and diabetes. Recent studies have demonstrated significant benefits of Semaglutide beyond glycemic co…
BACKGROUND: Incretin-based drugs, including glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs, are increasingly used in the management of type 2 diabetes mellitus and obesity…
Fifteen to forty% of patients experience recurrent weight gain (RWG) after metabolic bariatric surgery (MBS). Glucagon-like peptide receptor agonists (GLP-1 RAs) are effective treatments for obesity in nonsurgical patients. To assess the effects of s…
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) treat overweight or obesity with or without diabetes. This review aims to evaluate the effects of GLP-1 RAs on weight and cardiometabolic measures. This systematic review and meta-analysis of ra…
IMPORTANCE: Patients who have undergone bariatric surgery have an elevated risk for alcohol use disorder (AUD). Incretin-based therapies (IBTs) may be associated with reward pathways in addition to weight loss. OBJECTIVE: To evaluate whether IBT afte…
Obesity, hypertension, and chronic kidney disease (CKD) constitute the deadly trinity of modern threats for populations of both developed and developing countries. These diseases (together with type 2 diabetes) are closely linked in their pathophysio…
Coupling genetic profiling with electronic health records from hospital biobanks is a foundational resource for precision medicine. However, lack of ancestral heterogeneity limits discovery and generalizability. We leveraged the UCLA ATLAS Community…
The Farnesoid-X-receptor (FXR) is a bile sensor involved in the regulation of bile acid homeostasis, fibrosis, inflammation, and metabolism. Obeticholic acid (OCA), a semisynthetic derivative of chenodeoxycholic acid (CDCA), initially named 6-ethyl-C…
IMPORTANCE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for weight loss, but their ocular effects in nondiabetic individuals remain unclear. Prior studies suggest GLP-1RA use reduced age-related macular degeneration (AM…
Semaglutide is a glucagon-like-peptide-1 receptor agonist (GLP-1 RA) that is approved for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Common adverse drug reactions (ADR) of semaglutide include nausea, vomiting, abdominal pain, const…